Form 4: REGENXBIO Inc. Executive Steve Pakola Reports Stock Transaction
SEC Form 4 Filing
Chief Medical Officer Steve Pakola of REGENXBIO Inc. reports disposition of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 1, 2025, Steve Pakola, Chief Medical Officer of REGENXBIO Inc., disposed of 5,263 shares of common stock to cover tax obligations.
- The shares were withheld at a price of $8.07 per share.
- Following the transaction, Pakola directly owns 210,717 shares of REGENXBIO Inc. common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reflects a standard transaction related to executive compensation and tax obligations.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine procedure.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of original grant of restricted stock units to the reporting person |
| 02/01/2025 | Date of transaction (disposal of shares for tax withholding) |
| 04/04/2025 | Date of signature for the report |
Keywords
REGENXBIO, RGNX, Steve Pakola, Chief Medical Officer, Form 4, Stock Transaction, Beneficial Ownership, Tax Withholding, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.